Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.CAS 번호13480-84-5
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 146.00 | |
5 mg | In stock | $ 350.00 | |
10 mg | In stock | $ 530.00 | |
25 mg | In stock | $ 859.00 | |
50 mg | In stock | $ 1,180.00 | |
100 mg | In stock | $ 1,590.00 | |
500 mg | In stock | $ 3,190.00 |
Description | Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.CAS 번호13480-84-5 |
In vivo | Iroxanadine improves the survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. The addition of Iroxanadine (0.1-1 μM) to the culture medium prior to hypoxia or at the start of reoxygenation significantly reduced the caspase-dependent apoptosis.[1] |
Synonyms | BRX005, BRX-235, BRX-005, BRX235, BRX 005, BRX 235 |
Molecular Weight | 260.33 |
Formula | C14H20N4O |
CAS No. | 203805-20-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (172.86 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Iroxanadine 203805-20-3 MAPK p38 MAPK BRX005 BRX-235 BRX-005 BRX235 BRX 005 BRX 235 inhibitor inhibit